Who Buys Irbesartan from India — 366 Importers Behind a $106.3M Market
India's irbesartan import market is served by 366 active buyers who collectively imported $106.3M across 2,669 shipments. MACLEODS PHARMA USA,INC (UNITED STATES) leads with a 18.6% market share, followed by MACLEODS PHARMA USA,INC, and NEOETHICALS, S.A,. The top 5 buyers together control 46.0% of total import value, reflecting a moderately competitive buyer landscape.
Top Irbesartan Importers — Ranked by Import Value
MACLEODS PHARMA USA,INC (UNITED STATES) is the leading irbesartan importer from India, holding a 18.6% share of the $106.3M market across 2,669 shipments from 366 buyers. The top 5 buyers — MACLEODS PHARMA USA,INC (UNITED STATES), MACLEODS PHARMA USA,INC, (UNITED STATES), NEOETHICALS, S.A, (NICARAGUA), CSP VIATRIS SANTE AT CSP- LAB, (FRANCE), NUEVOS ETICOS NEOETHICALS, S.A. (GUATEMALA) — collectively control 46.0% of total import value.
Top Irbesartan Buyers & Importers
Ranked by import value · 366 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | MACLEODS PHARMA USA,INCUNITED STATES IRBESARTAN TABLETS USP 75MG 1X90SIRBESARTAN TABLETS USP 300MG 1X90S | $19.8M | 5 | 18.6% |
| 2 | MACLEODS PHARMA USA,INC,UNITED STATES IRBESARTAN TABLETS USP 75MG 1X90SIRBESARTAN TABLETS USP 300MG 1X90S | $12.3M | 5 | 11.6% |
| 3 | NEOETHICALS, S.A,NICARAGUA IRBESARTAN TABLETS USP 300MGIRBESARTAN TABLETS BP 300MG (103000X10XIRBESARTAN TABLETS USP 150MG | $6.9M | 5 | 6.5% |
| 4 | CSP VIATRIS SANTE AT CSP- LAB,FRANCE HARMLESS MEDICINES, IRBESARTAN / HYDROCHIRBESARTAN / HYDROCHLOROTHIAZIDE MYLAN 3IRBESARTAN TABLETS 150MG (IRBESARTAN ARR | $5.8M | 5 | 5.5% |
| 5 | NUEVOS ETICOS NEOETHICALS, S.A.GUATEMALA IRBESARTAN TABLETS USP 300MGIRBESARTAN TABLETS BP 300MG (103000X10XIRBESARTAN TABLETS USP 150MG | $4.1M | 5 | 3.9% |
| 6 | MACLEODS PHARMA USA INCUNITED STATES IRBESARTAN TABLETS USP 75MG 1X90SIRBESARTAN TABLETS USP 300MG 1X90S | $3.7M | 5 | 3.5% |
| 7 | APOTEX PTY LTD.AUSTRALIA IRBESARTAN TABLETS 150 MGIRBESARTAN TABLETS 300 MGABISART HCTZ TABLETS 150/12.5MG [11760 PACKS | $3.1M | 5 | 2.9% |
| 8 | YUSEN LOGISTICS BENELUX BELGIUMBELGIUM IRBESARTAN TABLETS 300MG [6119 PACK X 7X14'S] (IRBESARTAN+HYDROCHLOROTHIAZIDE TABLETS 3IRBESARTAN 300MG FCT 2X14 JUB, BATCH-IR3 | $2.6M | 5 | 2.4% |
| 9 | CSP MYLAN SAS AT CSP- LABO 274,FRANCE HARMLESS MEDICINES, IRBESARTAN / HYDROCHIRBESARTAN / HYDROCHLOROTHIAZIDE MYLAN 3IRBESARTAN TABLETS 150MG (IRBESARTAN ARR | $2.0M | 5 | 1.9% |
| 10 | ARROW GENERIQUES,FRANCE HARMLESS MEDICINES, IRBESARTAN / HYDROCHIRBESARTAN TABLETS 150 MGIRBESARTAN / HYDROCHLOROTHIAZIDE MYLAN 3 | $2.0M | 5 | 1.9% |
| 11 | CSP MYLAN SAS AT CSP LABO 274FRANCE HARMLESS MEDICINES, IRBESARTAN / HYDROCHIRBESARTAN / HYDROCHLOROTHIAZIDE MYLAN 3IRBESARTAN TABLETS 150MG (IRBESARTAN ARR | $1.8M | 5 | 1.7% |
| 12 | ANPHAR SA DE CVHONDURAS IRBESARTAN TABLETS USP 300MGIRBESARTAN TABLETS BP 300MG (103000X10XIRBESARTAN TABLETS BP 300MG (85000X10X1 | $1.3M | 5 | 1.2% |
| 13 | MYLAN HUNGARY KFT,HUNGARY HARMLESS MEDICINES, IRBESARTAN / HYDROCHIRBESARTAN / HYDROCHLOROTHIAZIDE MYLAN 3HARMLESS MEDICINES, IRBESARTAN AND HYDRO | $1.2M | 5 | 1.1% |
| 14 | TEVA CANADA LIMITEDCANADA HARMLESS MEDICINES, IRBESARTAN AND HYDROIRBESARTAN TAB 300MGIRBESARTAN TAB 150MG | $1.2M | 5 | 1.1% |
| 15 | XXLANXXRELXXD LXXITEXHUNGARY HARMLESS MEDICINES, IRBESARTAN / HYDROCHIRBESARTAN / HYDROCHLOROTHIAZIDE MYLAN 3HARMLESS MEDICINES, IRBESARTAN AND HYDRO | $1.1M | 5 | 1.0% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Irbesartan — and from which countries?
Flow of Irbesartan exports from India: each country's share and the named importers behind the numbers
Irbesartan — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $39.5M through 150 shipments. This represents a market share of 37.2% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• MACLEODS PHARMA USA,INC - $19.8M (50.0% of country's total business)
• MACLEODS PHARMA USA,INC, - $12.3M (31.1% of country's total business)
• MACLEODS PHARMA USA INC - $3.7M (9.3% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $263.7K, indicating premium pricing strategy compared to the market average of $39.8K.
United States is a key market for Irbesartan imports, representing 37.2% of total trade value.
2France
France emerges as the second largest importing country, achieving a total trade value of $16.4M through 182 shipments. This represents a market share of 15.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: France has a diverse importer base, with their top importers including:
• CSP VIATRIS SANTE AT CSP- LAB, - $5.8M (35.3% of country's total business)
• CSP MYLAN SAS AT CSP- LABO 274, - $2.0M (12.3% of country's total business)
• ARROW GENERIQUES, - $2.0M (12.1% of country's total business)
• CSP MYLAN SAS AT CSP LABO 274 - $1.8M (10.8% of country's total business)
• CSP VIATRIS SANTE AT CSP- LAB - $1.0M (6.1% of country's total business)
• Rest of France's importers - $3.8M (23.4% of country's total business)
Key Insight: France demonstrates strong market positioning with an average shipment value of $90.2K, indicating premium pricing strategy compared to the market average of $39.8K.
France is a key market for Irbesartan imports, representing 15.4% of total trade value.
3Australia
Australia emerges as the third largest importing country, achieving a total trade value of $8.4M through 106 shipments. This represents a market share of 7.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Australia has a diverse importer base, with their top importers including:
• APOTEX PTY LTD. - $3.1M (37.1% of country's total business)
• APOTEX PTY. LTD. - $1.1M (13.0% of country's total business)
• APOTEX PTY LTD - $1.1M (12.7% of country's total business)
Key Insight: Australia demonstrates strong market positioning with an average shipment value of $79.2K, indicating premium pricing strategy compared to the market average of $39.8K.
Australia is a key market for Irbesartan imports, representing 7.9% of total trade value.
4Nicaragua
Nicaragua emerges as the fourth largest importing country, achieving a total trade value of $7.6M through 12 shipments. This represents a market share of 7.2% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Nicaragua has a diverse importer base, with their top importers including:
• NEOETHICALS, S.A, - $6.9M (90.1% of country's total business)
Key Insight: Nicaragua demonstrates strong market positioning with an average shipment value of $636.5K, indicating premium pricing strategy compared to the market average of $39.8K.
Nicaragua is a key market for Irbesartan imports, representing 7.2% of total trade value.
5Belgium
Belgium emerges as the fifth largest importing country, achieving a total trade value of $5.4M through 144 shipments. This represents a market share of 5.1% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Belgium has a diverse importer base, with their top importers including:
• YUSEN LOGISTICS BENELUX BELGIUM - $2.6M (48.0% of country's total business)
Key Insight: Belgium demonstrates strong market positioning with an average shipment value of $37.6K, indicating competitive pricing strategy compared to the market average of $39.8K.
Belgium is a key market for Irbesartan imports, representing 5.1% of total trade value.
Buyer Segment Analysis
TransData Nexus Irbesartan buyer market intelligence
1Buyer Segment Analysis
The importation of Irbesartan from India involves various buyer segments, each with distinct purchasing behaviors:
- Distributors: Entities like MACLEODS PHARMA USA, INC. (United States) and APOTEX PTY LTD. (Australia) function as intermediaries, procuring large quantities to supply to pharmacies, hospitals, and healthcare providers. Their purchasing patterns are characterized by bulk orders to maintain consistent supply chains.
- Contract Manufacturers: Companies such as CSP VIATRIS SANTE AT CSP-LAB (France) and CSP MYLAN SAS AT CSP-LABO 274 (France) import Irbesartan for incorporation into their own pharmaceutical products. Their procurement is aligned with production schedules, leading to regular, sizable orders.
- Re-exporters: Firms like YUSEN LOGISTICS BENELUX BELGIUM (Belgium) specialize in importing pharmaceuticals for redistribution to other markets. Their purchasing behavior is influenced by global demand trends, resulting in variable order sizes and frequencies.
- Government Procurement: Entities such as NEOETHICALS, S.A. (Nicaragua) and NUEVOS ETICOS NEOETHICALS, S.A. (Guatemala) often engage in tender-based purchasing to supply public healthcare systems. Their orders are typically large and periodic, corresponding with government procurement cycles.
Understanding these segments is crucial for tailoring supply strategies to meet the specific needs and purchasing behaviors of each buyer type.
Country-Specific Import Regulations
TransData Nexus Irbesartan buyer market intelligence
1Country-Specific Import Regulations
Importing Irbesartan into the top five countries involves navigating specific regulatory frameworks:
- United States:
- Regulatory Authority: Food and Drug Administration (FDA).
- Import Registration Process: Requires submission of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), including comprehensive data on safety, efficacy, and manufacturing.
- Estimated Timeline: Typically 10 to 12 months for ANDA approval.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049079 are generally duty-free.
- France:
- Regulatory Authority: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).
- Import Registration Process: Requires a Marketing Authorization Application (MAA) with detailed product information.
- Estimated Timeline: Approximately 210 days for standard applications.
- Import Tariff/Duty: Medicaments under HS Code 30049079 are subject to a 0% duty rate.
- Australia:
- Regulatory Authority: Therapeutic Goods Administration (TGA).
- Import Registration Process: Requires inclusion in the Australian Register of Therapeutic Goods (ARTG), involving submission of quality, safety, and efficacy data.
- Estimated Timeline: Approximately 12 months for standard evaluations.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049079 are generally duty-free.
- Nicaragua:
- Regulatory Authority: Ministerio de Salud (MINSA).
- Import Registration Process: Requires a Sanitary Registration, including product dossiers and compliance with local standards.
- Estimated Timeline: Approximately 6 to 9 months.
- Import Tariff/Duty: Specific tariff information for HS Code 30049079 is not readily available; consultation with local customs authorities is recommended.
- Belgium:
- Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
- Import Registration Process: Requires a Marketing Authorization, involving submission of comprehensive product data.
- Estimated Timeline: Approximately 210 days for standard applications.
- Import Tariff/Duty: Medicaments under HS Code 30049079 are subject to a 0% duty rate.
Compliance with these regulations is essential for market entry and sustained operations in these countries.
Demand Drivers & Market Opportunity
TransData Nexus Irbesartan buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Irbesartan is primarily driven by the global prevalence of hypertension, a condition affecting approximately 1.28 billion adults worldwide as of 2021, according to the World Health Organization (WHO). The inclusion of Irbesartan in the WHO's Essential Medicines List underscores its significance in managing this widespread health issue.
Government healthcare programs and the expansion of universal health coverage in many countries have increased access to essential medications like Irbesartan. Tender-based procurement processes, often utilized by public health systems and international organizations, further stimulate demand. The presence of 366 buyers across 68 countries, as per TransData Nexus data, indicates a robust and diverse market for Irbesartan, presenting substantial opportunities for suppliers.
Common Questions — Irbesartan Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest irbesartan buyer importing from India?
Based on import volume and value, MACLEODS PHARMA USA,INC (UNITED STATES) leads with $19.8M in imports and a 18.6% market share — the highest of any single irbesartan importer. MACLEODS PHARMA USA,INC, (UNITED STATES) and NEOETHICALS, S.A, (NICARAGUA) are the next largest buyers.
QHow many companies buy irbesartan from India?
There are 366 active irbesartan buyers importing from India, with a combined market of $106.3M across 2,669 shipments to 68 countries. The top 5 buyers hold 46.0% of total import value, while the remaining 361 buyers handle the other 54.0%.
QWhich countries import the most irbesartan from India?
The top importing countries for irbesartan from India are United States (37.2%), France (15.4%), Australia (7.9%), Nicaragua (7.2%), Belgium (5.1%). These markets represent the largest demand centres for Indian pharmaceutical exports of irbesartan, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for irbesartan from India?
The average import transaction value for irbesartan from India is $39.8K, with an average unit price of $18.72 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Irbesartan buyer market intelligence
1Buyer Segment Analysis
The importation of Irbesartan from India involves various buyer segments, each with distinct purchasing behaviors:
- Distributors: Entities like MACLEODS PHARMA USA, INC. (United States) and APOTEX PTY LTD. (Australia) function as intermediaries, procuring large quantities to supply to pharmacies, hospitals, and healthcare providers. Their purchasing patterns are characterized by bulk orders to maintain consistent supply chains.
- Contract Manufacturers: Companies such as CSP VIATRIS SANTE AT CSP-LAB (France) and CSP MYLAN SAS AT CSP-LABO 274 (France) import Irbesartan for incorporation into their own pharmaceutical products. Their procurement is aligned with production schedules, leading to regular, sizable orders.
- Re-exporters: Firms like YUSEN LOGISTICS BENELUX BELGIUM (Belgium) specialize in importing pharmaceuticals for redistribution to other markets. Their purchasing behavior is influenced by global demand trends, resulting in variable order sizes and frequencies.
- Government Procurement: Entities such as NEOETHICALS, S.A. (Nicaragua) and NUEVOS ETICOS NEOETHICALS, S.A. (Guatemala) often engage in tender-based purchasing to supply public healthcare systems. Their orders are typically large and periodic, corresponding with government procurement cycles.
Understanding these segments is crucial for tailoring supply strategies to meet the specific needs and purchasing behaviors of each buyer type.
Country-Specific Import Regulations
TransData Nexus Irbesartan buyer market intelligence
1Country-Specific Import Regulations
Importing Irbesartan into the top five countries involves navigating specific regulatory frameworks:
- United States:
- Regulatory Authority: Food and Drug Administration (FDA).
- Import Registration Process: Requires submission of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), including comprehensive data on safety, efficacy, and manufacturing.
- Estimated Timeline: Typically 10 to 12 months for ANDA approval.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049079 are generally duty-free.
- France:
- Regulatory Authority: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).
- Import Registration Process: Requires a Marketing Authorization Application (MAA) with detailed product information.
- Estimated Timeline: Approximately 210 days for standard applications.
- Import Tariff/Duty: Medicaments under HS Code 30049079 are subject to a 0% duty rate.
- Australia:
- Regulatory Authority: Therapeutic Goods Administration (TGA).
- Import Registration Process: Requires inclusion in the Australian Register of Therapeutic Goods (ARTG), involving submission of quality, safety, and efficacy data.
- Estimated Timeline: Approximately 12 months for standard evaluations.
- Import Tariff/Duty: Pharmaceutical products under HS Code 30049079 are generally duty-free.
- Nicaragua:
- Regulatory Authority: Ministerio de Salud (MINSA).
- Import Registration Process: Requires a Sanitary Registration, including product dossiers and compliance with local standards.
- Estimated Timeline: Approximately 6 to 9 months.
- Import Tariff/Duty: Specific tariff information for HS Code 30049079 is not readily available; consultation with local customs authorities is recommended.
- Belgium:
- Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).
- Import Registration Process: Requires a Marketing Authorization, involving submission of comprehensive product data.
- Estimated Timeline: Approximately 210 days for standard applications.
- Import Tariff/Duty: Medicaments under HS Code 30049079 are subject to a 0% duty rate.
Compliance with these regulations is essential for market entry and sustained operations in these countries.
Demand Drivers & Market Opportunity
TransData Nexus Irbesartan buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Irbesartan is primarily driven by the global prevalence of hypertension, a condition affecting approximately 1.28 billion adults worldwide as of 2021, according to the World Health Organization (WHO). The inclusion of Irbesartan in the WHO's Essential Medicines List underscores its significance in managing this widespread health issue.
Government healthcare programs and the expansion of universal health coverage in many countries have increased access to essential medications like Irbesartan. Tender-based procurement processes, often utilized by public health systems and international organizations, further stimulate demand. The presence of 366 buyers across 68 countries, as per TransData Nexus data, indicates a robust and diverse market for Irbesartan, presenting substantial opportunities for suppliers.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 366 global importers of Irbesartan identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 2,669 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 68 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,669 Verified Shipments
366 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists